{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T01:34:13Z","timestamp":1772674453028,"version":"3.50.1"},"reference-count":43,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: Molecular profiling guides cancer treatment, by identifying actionable genomic alterations. The IMPRESS-Norway trial (NCT04817956) is a nation-wide precision medicine trial evaluating the efficacy of approved cancer drugs on a novel indication in patients with advanced cancers harbouring potentially actionable alterations. Trametinib, a selective MEK1\/2 inhibitor targeting the Mitogen-Activated Protein Kinase (MAPK) signalling pathway, is approved for BRAF V600 mutant melanoma but may also show activity in tumours with other alterations. This sub-study aimed to assess the efficacy of trametinib monotherapy across tumour types with alterations activating the MAPK signalling pathway.Patient\/material and methods: In the IMPRESS-Norway trial patients are screened with the TruSight Oncology 500 panel or circulating tumour DNA profiling. Eligible patients are offered biomarker matched targeted therapies. In this subgroup analysis, we identified patients treated with trametinib monotherapy. Primary endpoints were disease control rate (DCR) after 16 weeks and safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS).Results: DCR after 16 weeks of treatment was 39% in 52 response evaluable patients, with four patients (8%) experiencing partial response, and 16 (31%) stable disease. Responses were seen in tumours harbouring BRAF fusions, GNA11, GNAQ, KRAS, NF1, and NRAS alterations, most frequently in low-grade serous ovarian cancer, central nervous system tumours, and uveal melanoma. Forty-eight percent of patients experienced treatment-related adverse events, including two treatment related deaths. Median PFS and OS were 4 and 9 months, respectively. Interpretation: Trametinib monotherapy achieved a 39% DCR in patients lacking standard options, supporting further studies to confirm efficacy and identify predictive biomarkers for treatment response.<\/jats:p>","DOI":"10.2340\/1651-226x.2026.45086","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T09:40:49Z","timestamp":1770716449000},"page":"90-96","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial"],"prefix":"10.2340","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0538-4977","authenticated-orcid":false,"given":"Kathinka Schmidt","family":"Sl\u00f8rdahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7681-5949","authenticated-orcid":false,"given":"Katarina","family":"Puco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8543-2213","authenticated-orcid":false,"given":"Ragnhild S\u00f8rum","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8886-3584","authenticated-orcid":false,"given":"Ingrid","family":"Dyvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3218-933X","authenticated-orcid":false,"given":"Sigmund","family":"Brabrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3247-5241","authenticated-orcid":false,"given":"Pitt","family":"Niehusmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5101-3891","authenticated-orcid":false,"given":"Eli Sihn Samdal","family":"Steinskog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-6767","authenticated-orcid":false,"given":"Egil S.","family":"Blix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-425X","authenticated-orcid":false,"given":"\u00c5smund","family":"Flobak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3245-8544","authenticated-orcid":false,"given":"Irja Alida","family":"Oppedal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6640-3927","authenticated-orcid":false,"given":"Sebastian","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-3046","authenticated-orcid":false,"given":"Cecilie Fredvik","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3672-9090","authenticated-orcid":false,"given":"Hanne","family":"Blakstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-0175","authenticated-orcid":false,"given":"Kristina","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5743-8244","authenticated-orcid":false,"given":"Sigbj\u00f8rn","family":"Smeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Amundsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-4697","authenticated-orcid":false,"given":"Kjetil","family":"Task\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5520-0275","authenticated-orcid":false,"given":"\u00c5slaug","family":"Helland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"141113","doi-asserted-by":"crossref","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bi\u00e8che I, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35(7):588\u2013606.","DOI":"10.1016\/j.annonc.2024.04.005"},{"key":"141114","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005","DOI":"10.1016\/j.annonc.2024.04.005"},{"key":"141115","doi-asserted-by":"crossref","unstructured":"Helland \u00c5, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, et al. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J Transl Med. 2022;20(1):225.","DOI":"10.1186\/s12967-022-03432-5"},{"key":"141116","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12967-022-03432-5","DOI":"10.1186\/s12967-022-03432-5"},{"key":"141117","doi-asserted-by":"crossref","unstructured":"Puco K, Fagereng GL, Brabrand S, Niehusmann P, St\u00f8re Blix E, Samdal Steinskog ES, et al. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results. Acta Oncol. 2024;63:379\u201384.","DOI":"10.2340\/1651-226X.2024.28322"},{"key":"141118","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/1651-226x.2024.28322","DOI":"10.2340\/1651-226X.2024.28322"},{"key":"141119","doi-asserted-by":"crossref","unstructured":"Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011;17(5):989\u20131000.","DOI":"10.1158\/1078-0432.CCR-10-2200"},{"key":"141120","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-2200","DOI":"10.1158\/1078-0432.CCR-10-2200"},{"key":"141121","doi-asserted-by":"crossref","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107\u201314.","DOI":"10.1056\/NEJMoa1203421"},{"key":"141122","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1203421","DOI":"10.1056\/NEJMoa1203421"},{"key":"141123","doi-asserted-by":"crossref","unstructured":"Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311(23):2397\u2013405.","DOI":"10.1001\/jama.2014.6096"},{"key":"141124","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jama.2014.6096","DOI":"10.1001\/jama.2014.6096"},{"key":"141125","doi-asserted-by":"crossref","unstructured":"Cleary JM, Wang V, Heist RS, Kopetz ES, Mitchell EP, Zwiebel JA, et al. Differential outcomes in Codon 12\/13 and Codon 61 NRAS-mutated cancers in the phase II NCI-MATCH trial of Binimetinib in patients with NRAS-mutated tumors. Clin Cancer Res. 2021;27(11):2996\u20133004.","DOI":"10.1158\/1078-0432.CCR-21-0066"},{"key":"141126","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0066","DOI":"10.1158\/1078-0432.CCR-21-0066"},{"key":"141127","doi-asserted-by":"crossref","unstructured":"Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435\u201345.","DOI":"10.1016\/S1470-2045(17)30180-8"},{"key":"141128","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s1470-2045(17)30180-8","DOI":"10.1016\/S1470-2045(17)30180-8"},{"key":"141129","doi-asserted-by":"crossref","unstructured":"Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial. Lancet. 2022;399(10324):541\u201353.","DOI":"10.1016\/S0140-6736(21)02175-9"},{"key":"141130","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s0140-6736(21)02175-9","DOI":"10.1016\/S0140-6736(21)02175-9"},{"key":"141131","doi-asserted-by":"crossref","unstructured":"Klesse LJ, Jordan JT, Radtke HB, Rosser T, Schorry E, Ullrich N, et al. The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities. Oncologist. 2020;25(7):e1109\u201316.","DOI":"10.1634\/theoncologist.2020-0069"},{"key":"141132","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0069","DOI":"10.1634\/theoncologist.2020-0069"},{"key":"141133","doi-asserted-by":"crossref","unstructured":"Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, et al. MILO\/ENGOT-ov11: binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J Clin Oncol. 2020;38(32):3753\u201362.","DOI":"10.1200\/JCO.20.01164"},{"key":"141134","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/jco.20.01164","DOI":"10.1200\/JCO.20.01164"},{"key":"141135","doi-asserted-by":"crossref","unstructured":"Yan J, Wu X, Yu J, Yu H, Xu T, Brown KM, et al. Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor. Eur J Cancer. 2018;89:90\u2013101.","DOI":"10.1016\/j.ejca.2017.11.011"},{"key":"141136","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2017.11.011","DOI":"10.1016\/j.ejca.2017.11.011"},{"key":"141137","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"141138","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"141139","doi-asserted-by":"crossref","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963\u201372.","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"141140","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/jco.2009.26.3541","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"141141","doi-asserted-by":"crossref","unstructured":"van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583\u201393.","DOI":"10.1016\/S1470-2045(11)70057-2"},{"key":"141142","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s1470-2045(11)70057-2","DOI":"10.1016\/S1470-2045(11)70057-2"},{"key":"141143","doi-asserted-by":"crossref","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395\u20138.","DOI":"10.1182\/blood-2013-03-488098"},{"key":"141144","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2013-03-488098","DOI":"10.1182\/blood-2013-03-488098"},{"key":"141145","doi-asserted-by":"crossref","unstructured":"Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024;35(3):248\u201366.","DOI":"10.1016\/j.annonc.2023.11.015"},{"key":"141146","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2023.11.015","DOI":"10.1016\/j.annonc.2023.11.015"},{"key":"141147","doi-asserted-by":"crossref","unstructured":"Silva-Rodr\u00edguez P, Fern\u00e1ndez-D\u00edaz D, Bande M, Pardo M, Loidi L, Blanco-Teijeiro MJ. GNAQ and GNA11 genes: a comprehensive review on oncogenesis, prognosis and therapeutic opportunities in uveal melanoma. Cancers (Basel). 2022;14(13).","DOI":"10.3390\/cancers14133066"},{"key":"141148","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers14133066","DOI":"10.3390\/cancers14133066"},{"key":"141149","doi-asserted-by":"crossref","unstructured":"Steeb T, Wessely A, Ruzicka T, Heppt MV, Berking C. How to MEK the best of uveal melanoma: a systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. Eur J Cancer. 2018;103:41\u201351.","DOI":"10.1016\/j.ejca.2018.08.005"},{"key":"141150","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2018.08.005","DOI":"10.1016\/j.ejca.2018.08.005"},{"key":"141151","doi-asserted-by":"crossref","unstructured":"Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018;36(12):1232\u20139.","DOI":"10.1200\/JCO.2017.74.1090"},{"key":"141152","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/jco.2017.74.1090","DOI":"10.1200\/JCO.2017.74.1090"},{"key":"141153","doi-asserted-by":"crossref","unstructured":"Capper D, Reifenberger G, French PJ, Schweizer L, Weller M, Touat M, et al. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology. 2023;25(5):813\u201326.","DOI":"10.1093\/neuonc\/noad008"},{"key":"141154","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/neuonc\/noad008","DOI":"10.1093\/neuonc\/noad008"},{"key":"141155","unstructured":"Agency EM. Trametinib (Mekinist) [Summary of Product Characteristics]: European Medicines Agency; 2024 [updated 2025 Jan 10; cited 2025 Nov 23]. Available from: https:\/\/www.ema.europa.eu."}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45086\/52826","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45086\/52826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T09:41:07Z","timestamp":1770716467000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/45086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":43,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2026.45086","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}